FUBIMINA : Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ 9-Tetrahydrcannabinol-Like Effects in Mice

Diversion of synthetic cannabinoids for abuse began in the early 2000s. Despite legislation banning compounds currently on the drug market, illicit manufacturers continue to release new compounds for recreational use. This study examined new synthetic cannabinoids ABCHMINACA, AB-PINACA, and FUBIMINA, with the hypothesis that these compounds, like those before them, would be highly susceptible to abuse. Cannabinoids were examined in vitro for binding and activation of CB1 receptors, and in vivo for pharmacological effects in mice and in Δ-THC discrimination. AB-CHMINACA, AB-PINACA and FUBIMINA bound to and activated CB1 and CB2 receptors, and produced locomotor suppression, antinociception, hypothermia, and catalepsy. Further, these compounds, along with JWH-018, CP47,497, and WIN55,212-2, substituted for Δ-THC in Δ-THC discrimination. Rank order of potency correlated with CB1 receptor binding affinity, and all three compounds were full agonists in [S]GTPγS binding, as compared to the partial agonist Δ-THC. Indeed, AB-CHMINACA and AB-PINACA exhibited higher efficacy than most known full agonists of the CB1 receptor. Preliminary analysis of urinary metabolites of the compounds revealed the expected hydroxylation. AB-PINACA and AB-CHMINACA are of potential interest as research tools due to their unique chemical structures and high CB1 receptor efficacies. Further studies on these chemicals is likely to include research on understanding cannabinoid receptors and other components of the endocannabinoid system that underlie the abuse of synthetic cannabinoids. This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on June 23, 2015 as DOI: 10.1124/jpet.115.225326 at A PE T Jornals on O cber 9, 2017 jpet.asjournals.org D ow nladed from

[1]  B. Thomas,et al.  Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs. , 2012, Analytical chemistry.

[2]  M. Damaj,et al.  Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor. , 2010, Journal of medicinal chemistry.

[3]  I. Vardakou,et al.  Spice drugs as a new trend: mode of action, identification and legislation. , 2010, Toxicology letters.

[4]  J. Warner,et al.  Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. , 2009, European journal of pharmacology.

[5]  T. Tuccinardi,et al.  Indoles and related compounds as cannabinoid ligands. , 2008, Mini reviews in medicinal chemistry.

[6]  L. Padgett,et al.  Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. , 2005, Current medicinal chemistry.

[7]  Z. Vogel,et al.  2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Griffin,et al.  Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. , 1998, The Journal of pharmacology and experimental therapeutics.

[9]  D. R. Compton,et al.  Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. , 1996, The Journal of pharmacology and experimental therapeutics.

[10]  R. L. Barrett,et al.  Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats , 1995, Neuropharmacology.

[11]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[12]  K. Rice,et al.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. , 1993, The Journal of pharmacology and experimental therapeutics.

[13]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[14]  L. Gold,et al.  Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. , 1992, The Journal of pharmacology and experimental therapeutics.

[15]  R. L. Barrett,et al.  A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. , 1992, The Journal of pharmacology and experimental therapeutics.

[16]  R. Mechoulam,et al.  Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs , 1991, Pharmacology Biochemistry and Behavior.

[17]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[18]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .

[19]  Satoru Matsuda,et al.  Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products , 2013, Forensic Toxicology.

[20]  M. Johnson,et al.  Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. , 1992, The Journal of pharmacology and experimental therapeutics.